Typically, CeD patients consuming gluten have serum antibodies (IgA, IgG, IgM) to the autoantigen transglutaminase 2 (TG2) (19, 20) and to deamidated gluten peptides (DGP) (21–23). This evidence concerns the gene TGM2 and cranioectodermal dysplasia.